

Alicja Dębska-Ślizień, Leszek Tylicki

Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk

Year 2022 in RDTF, how it looked like?

Dear Readers,

We are starting the second year of our journal in a new English version. We believe that we have managed to create a quarterly that combines the form of an educational platform helpful in the postgraduate education process and at the same time a place for presenting the results of scientific research. At the current stage of efforts to indexation of the journal in the scientific databases, it is very important to regularly publish subsequent issues. To achieve this, in addition to the inflow of new manuscripts, a timely review process was necessary. We have achieved this thanks to the invaluable help of the expert reviewers listed in Table 1, to whom we would like to thank.

The past year was full of important achievements in nephrology. It is worth mentioning at least the publication of groundbreaking evidence for the treatment of patients with chronic kidney disease on the nephroprotective potential of SGLT-2 inhibitors, both in patients with diabetic and non-diabetic kidney disease [1, 2]. This achievement was also reflected in our quarterly, where we published several papers on this issue last year [3, 4]. Review articles on the principles of using a low-protein diet and hypoxia-inducible factor-prolyl hydroxylase inhibitors, prolyl hydroxylase inhibitors,

a new group of drugs used in the treatment of anemia also met with great interest [5, 6].

In this year's first issue of the journal, which we are now giving you, we publish several interesting articles on the principles of communication with patients treated with peritoneal dialysis, the advantages of regular physical activity, the first part of the study on the history and physiological basis of bloodletting and an article on sudden cardiac death in early stages of renal replacement therapy.

Wishing you a pleasant reading, we leave you with the latest issue of the Renal Disease and Transplantation Forum.

CONFLICT OF INTEREST

None to declared.

Table 1. Alphabetical list of RDTF reviewers in 2022

Magdalena Durlik
Joanna Gotlib
Magdalena Jankowska
Dorota Kamińska
Sylvia Małgorzewicz
Tomasz Stompór
Monika Wieliczko
Aleksandra Żurkowska

- Herrington WG, Staplin N, Wanner C, et al. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2023; 388(2): 117–127, doi: [10.1056/NEJMoa2204233](https://doi.org/10.1056/NEJMoa2204233), indexed in Pubmed: [36331190](https://pubmed.ncbi.nlm.nih.gov/36331190/).
- Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet.* 2022; 400: 1788–1801.
- Nowicki M. Dapagliflozin - a breakthrough in the treatment of chronic kidney disease from the perspective of the DA-PA-CKD study. *Renal Disease and Transplantation Forum.* 2022; 15: 23–29, doi: [10.5603/RDTF.2021.0014](https://doi.org/10.5603/RDTF.2021.0014).
- Naumnik B. Dapagliflozin therapy for patients with CKD according to current guidelines and clinical trials. *Renal Disease and Transplantation Forum.* 2022; 15(3): 120–128, doi: [10.5603/RDTF.2022.0011](https://doi.org/10.5603/RDTF.2022.0011).
- Małgorzewicz S, Jankowska M, Niemczyk S, et al. Practical aspects of a low-protein diet. *Renal Disease and Transplantation Forum.* 2022; 15(4): 161–165, doi: [10.5603/RDTF.2023.0002](https://doi.org/10.5603/RDTF.2023.0002).
- Chamienia A, Dębska-Ślizień A. Roxadustat - new therapeutic option for treatment of anemia in patients with chronic kidney disease. *Renal Disease and Transplantation Forum.* 2022; 15(2): 63–74, doi: [10.5603/RDTF.2022.0010](https://doi.org/10.5603/RDTF.2022.0010).

REFERENCES